Browse result page of B3Pdb
The total number entries retrieved from this search are 137, scroll left/right for detailed information.
| B3pdbIDb3pdb_0003 | PEPTIDE NAMEK16ApoE | PEPTIDE SEQUENCE (1-letter)NA | PEPTIDE SEQUENCE (3-letter)NA | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH16 | PEPTIDE CONFORMATIONNA | PEPTIDE NATURECationic | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINEhCMEC/D3 monolayers | In vitro CONCENTRATIONNA | In vitro METHODLaser confocal microscopy | In vitro RESULTThe uptake of AF647-K16ApoE-targeted nanoparticles was substantially greater than the AF647-targeted | ANIMAL MODELWT mice | In vivo CONCENTRATION75 μg/μL | In vivo MODE OF DELIVERYNA | In vivo METHODInjected into the femoral vein of 2- year-old APP transgenic (Tg2576) mice | In vivo RESULTThe K16ApoE-targeted nanoparticles showed 8- to 10-fold higher accumulation in various brain regions | ACTIONIt enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONintracellular | COMBINATIONIt is given in the combination with IgG4.1 | PHYSICAL CONDITIONAlzheimer’s disease | RESPONSENA | RESULTNA | LABELNA | PMID 30300748 |
| B3pdbIDb3pdb_0041 | PEPTIDE NAMEOdorranalectin | PEPTIDE SEQUENCE (1-letter)YASPKSFRYPNGVLACT | PEPTIDE SEQUENCE (3-letter)TyrAlaSerProLysSerPheArgTyrProAsnGlyValLeuAlaCysThr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONConjugated with 5(6)-carboxyfluorescein at N-termi | PEPTIDE LENGTH17 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEfrog | SMILESN[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)NCC(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)O | CELL LINEhCMEC/D3 cells | In vitro CONCENTRATION2500 cells per cm square | In vitro METHODLC/MS and Fluorescence microscopy | In vitro RESULTIt shows the cellulr uptake of OL at the BBB endothelium. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONTAT-Modified MVIIA for Crossing the Blood-Brain Barrier | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONAlone | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31068126 |
| B3pdbIDb3pdb_0056 | PEPTIDE NAMEAPep2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONFAM is conjgated at the N-terminal | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0057 | PEPTIDE NAMEPPII(R8X) | PEPTIDE SEQUENCE (1-letter)VRLPPPVXLPPPVRLPPP | PEPTIDE SEQUENCE (3-letter)ValArgLeuProProProValXaaLeuProProProValArgLeuProProPro | N-TERMINAL MODIFICATIONCuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0058 | PEPTIDE NAMEPPII(R8K) | PEPTIDE SEQUENCE (1-letter)VRLPPPVKLPPPVRLPPP | PEPTIDE SEQUENCE (3-letter)ValArgLeuProProProValLysLeuProProProValArgLeuProProPro | N-TERMINAL MODIFICATIONAmide conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0059 | PEPTIDE NAMEPPII(L3X) | PEPTIDE SEQUENCE (1-letter)VRXPPPVRLPPPVRLPPP | PEPTIDE SEQUENCE (3-letter)ValArgXaaProProProValArgLeuProProProValArgLeuProProPro | N-TERMINAL MODIFICATIONCuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0060 | PEPTIDE NAMEPPII(L15X) | PEPTIDE SEQUENCE (1-letter)VRLPPPVRLPPPVRXPPP | PEPTIDE SEQUENCE (3-letter)ValArgLeuProProProValArgLeuProProProValArgXaaProProPro | N-TERMINAL MODIFICATIONCuACC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0061 | PEPTIDE NAMEPPII(L3X;L15X) | PEPTIDE SEQUENCE (1-letter)VRXPPPVRLPPPVRXPPP | PEPTIDE SEQUENCE (3-letter)ValArgXaaProProProValArgLeuProProProValArgXaaProProPro | N-TERMINAL MODIFICATIONCuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0062 | PEPTIDE NAMEPPII(L3X;V13X) | PEPTIDE SEQUENCE (1-letter)VRXPPPVRLPPPXRLPPP | PEPTIDE SEQUENCE (3-letter)ValArgXaaProProProValArgLeuProProProXaaArgLeuProProPro | N-TERMINAL MODIFICATIONCuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0063 | PEPTIDE NAMEPPII(L3X;L15K) | PEPTIDE SEQUENCE (1-letter)VRXPPPVRLPPPVRKPPP | PEPTIDE SEQUENCE (3-letter)ValArgXaaProProProValArgLeuProProProValArgLysProProPro | N-TERMINAL MODIFICATIONAmide and CuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0064 | PEPTIDE NAMEPPII(L3X;V13K) | PEPTIDE SEQUENCE (1-letter)VRXPPPVRLPPPKRLPPP | PEPTIDE SEQUENCE (3-letter)ValArgXaaProProProValArgLeuProProProLysArgLeuProProPro | N-TERMINAL MODIFICATIONAmide and CuAAC conjugated at N-terminus | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)N1[C@@]([H])(CCC1)C(=O)O | CELL LINEbEnd.3 cells | In vitro CONCENTRATIONNA | In vitro METHODImmunofluorescence microscopy | In vitro RESULTIt shows the permeability towards the BBB. | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONThese novel peptide conjugates have the capacity to act as promising brain shuttles | TRANSPORT TYPEReceptor-mediated transcytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONCombined | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 32055384 |
| B3pdbIDb3pdb_0065 | PEPTIDE NAMEAng-2 | PEPTIDE SEQUENCE (1-letter)CTFFYGGSRGKRNNFKTEE | PEPTIDE SEQUENCE (3-letter)CysThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGlu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELC57BL6 mice | In vivo CONCENTRATION1 mg/mL | In vivo MODE OF DELIVERYIntraperitoneal | In vivo METHODFluorescent microscopy | In vivo RESULTLocalization of the nanoparticle within the brain cells, highlighting in particular the neuron accum | ACTIONBrain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus | TRANSPORT TYPETranscytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONConjugated to poly(lactic-co-glycolic acid) (PLGA) | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 31963430 |
| B3pdbIDb3pdb_0153 | PEPTIDE NAMEApomin | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION200 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULTThe difference in peptide concentration between donor and acceptor cell was below 1%, indicate cells | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0154 | PEPTIDE NAMEApomin | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION200 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT1.7+/- 0.1 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0155 | PEPTIDE NAMEApoo | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION200 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT1.6+/- 0.2 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0156 | PEPTIDE NAMEApoo | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION100 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT2.3+/- 0.7 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0157 | PEPTIDE NAMEApomin | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION200 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT1.8+/- 0.1 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0158 | PEPTIDE NAMEApoo | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION200 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT1.7+/- 0.2 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0159 | PEPTIDE NAMEApoo | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINECaco-2 cell line | In vitro CONCENTRATION100 microliter of peptide | In vitro METHODBBB-RTU cell kit assay PAMPA method | In vitro RESULT2.5+/- 0.8 apparent permeability | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONCNS | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0163 | PEPTIDE NAMEASA-APOEII | PEPTIDE SEQUENCE (1-letter)LRKLRKRLLLRKLRKRLL | PEPTIDE SEQUENCE (3-letter)LeuArgLysLeuArgLysArgLeuLeuLeuArgLysLeuArgLysArgLeuLeu | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINECHO cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT32 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0164 | PEPTIDE NAMEAPO-Ang2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINECHO cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT13 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0168 | PEPTIDE NAMEASA-APOEII | PEPTIDE SEQUENCE (1-letter)LRKLRKRLLLRKLRKRLL | PEPTIDE SEQUENCE (3-letter)LeuArgLysLeuArgLysArgLeuLeuLeuArgLysLeuArgLysArgLeuLeu | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT19.3 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0169 | PEPTIDE NAMEAPO-Ang2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEbEND cell line | In vitro CONCENTRATION2.5 microgram/ ml | In vitro METHODcellular uptake assay | In vitro RESULT22.9 % cellular uptake | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0173 | PEPTIDE NAMEASA-APOEII | PEPTIDE SEQUENCE (1-letter)LRKLRKRLLLRKLRKRLL | PEPTIDE SEQUENCE (3-letter)LeuArgLysLeuArgLysArgLeuLeuLeuArgLysLeuArgLysArgLeuLeu | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEPBCECs cell line | In vitro CONCENTRATION0.02% cells were added | In vitro METHODBasolateral screening assay | In vitro RESULT150% transfer | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEBasolateral | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0174 | PEPTIDE NAMEAPO-Ang2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONConjugated with ASA drug | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINEPBCECs cell line | In vitro CONCENTRATION0.02% cells were added | In vitro METHODBasolateral screening assay | In vitro RESULT120% transfer | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEBasolateral | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONLysosomal disorder | RESPONSENA | RESULTNA | LABELNA | PMID 24573272 |
| B3pdbIDb3pdb_0175 | PEPTIDE NAMEAngiopep-2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONConjugated with Tratuzumab | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale Crl:Cd-1 nude mice | In vivo CONCENTRATION10mg/Kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODFluoroscent screening by FITC labbled peptide maass in brain tissue | In vivo RESULTSignificant fluoroscdnt observed in brain tissue | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONBreast cancer metastasis | RESPONSENA | RESULTNA | LABELNA | PMID 25492620 |
| B3pdbIDb3pdb_0176 | PEPTIDE NAMEAngiopep-2 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONConjugated with Tratuzumab | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale mice xenograft for BT 474 cell line intracerebrally | In vivo CONCENTRATION6 ml/kg | In vivo MODE OF DELIVERYIntravenous | In vivo METHODIn situ brain perfusion assay | In vivo RESULT10 time increase of Mab as compared to control in brain tissue | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONBreast cancer metastasis | RESPONSENA | RESULTNA | LABELNA | PMID 25492620 |
| B3pdbIDb3pdb_0199 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)DPQILMGVLRSIRGFGVKL | PEPTIDE SEQUENCE (3-letter)AspProGlnIleLeuMetGlyValLeuArgSerIleArgGlyPheGlyValLysLeu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0215 | PEPTIDE NAMEBacteriophage derive | PEPTIDE SEQUENCE (1-letter)LYVLHSRGLWGFKLAAALE | PEPTIDE SEQUENCE (3-letter)LeuTyrValLeuHisSerArgGlyLeuTrpGlyPheLysLeuAlaAlaAlaLeuGlu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDET7 Bacteiophage derived | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELMale wistar mice | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONCan cross BBB as well as Blood CSF barrier | TRANSPORT TYPETransendocytosis | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONAlzheimer | RESPONSENA | RESULTNA | LABELNA | PMID 26411801 |
| B3pdbIDb3pdb_0381 | PEPTIDE NAMEApamin | PEPTIDE SEQUENCE (1-letter)CNCKAPETALCARRCQQH | PEPTIDE SEQUENCE (3-letter)CysAsnCysLysAlaProGluThrAlaLeuCysAlaArgArgCysGlnGlnHis | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 24281722 |
| B3pdbIDb3pdb_0394 | PEPTIDE NAMEAngiopep-2 (AP2) | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGKRNNFKTEEY | PEPTIDE SEQUENCE (3-letter)ThrPhePheTyrGlyGlySerArgGlyLysArgAsnAsnPheLysThrGluGluTyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESbEnd.3 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODmouse | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID 24769213 |
| B3pdbIDb3pdb_0449 | PEPTIDE NAMEMelanin-concentratin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVYRPCWQV | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSENA | RESULTNA | LABELNA | PMID NA |
| B3pdbIDb3pdb_0468 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.000052 mL/(g x min) | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0469 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution volume | RESULT0.0153 ml/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0470 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.00137 ml/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0471 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.000594 mL/(g x min) | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0472 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% capillary | RESULT20% | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0473 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% parenchyma | RESULT80% | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0474 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODHPLC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT53.3 %/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0475 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODHPLC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT78.7 %/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0476 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODHPLC | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT83.3 %/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0477 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODShake Flask | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSELog P | RESULT-1.04 | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0804 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEhalf life, brain | RESULT11.36 min | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0805 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEBrain elemination rate constant | RESULT0.061 min-1 | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0806 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% capillary | RESULT22.50% | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0807 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% parenchyma | RESULT77.50% | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0808 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional influx rate constant | RESULT0.00037 mL/(g x min) | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0809 | PEPTIDE NAMEApi88 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL-NH2 | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Val-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIntravenous | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial disrobution volume | RESULT0.02606 ml/g | LABELDirect iodination | PMID 22594381 |
| B3pdbIDb3pdb_0810 | PEPTIDE NAMEApidaecin Api137 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Va-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODEfflux study ICU | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEBrain elemination rate constant | RESULT-0.022 min-1 | LABELDirect iodination | PMID 24164260 |
| B3pdbIDb3pdb_0811 | PEPTIDE NAMEApidaecin Api137 | PEPTIDE SEQUENCE (1-letter)Guan-ONNRPVYIPRPRPPHPRL | PEPTIDE SEQUENCE (3-letter)Guan-Orn-Asn-Asn-Arg-Pro-Va-Tyr-Ile-Pro-Arg-Pro-Arg-Pro-Pro-His-Pro-Arg-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODCapillary depletion | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYNA | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% capillary | RESULT23% | LABELDirect iodination | PMID 24164260 |